Another TRPA1 antagonist, oral GRC17536 (Figure 3b and Figure 4b), was able to finish a phase II clinical trial as a promising treatment for diabetic neuropathy but was not able to advance to phase III, due to its limited bioavailability and pharmacokinetic profile [155]. Here, TRPA1 is linked to diabetic neuropathy.